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Human polyomaviruses (HPyVs) asymptomatically infect the human population establishing latency 
in the host and their seroprevalence can reach 90% in healthy adults. Few studies have focused on 
the pediatric population and there are no reports regarding the seroprevalence of all the newly isolated 
HPyVs among Italian children. Therefore, we investigated the frequency of serum antibodies against 
12 PyVs in 182 immunocompetent children from Northeast Italy, by means of a multiplex antibody 
detection system. Additionally, secondary lymphoid tissues were collected to analyze the presence of 
HPyVs DNA sequences using a specific Real Time PCRs or PCRs. Almost 100% of subjects were 
seropositive for at least one PyV. Seropositivity ranged from 3% for antibodies against Simian virus 
40 (SV40) in children from 0 to 3 years, to 91% for antibodies against WU polyomavirus (WUPyV) 
and HPyV10 in children from 8 to 17 years. The mean number of PyV for which children were 
seropositive increased with the increasing of age: 4 standard deviations (SD) 1.8 in the 0-3 years 
group, 5 (SD 1.9) in the 4-7 years group, and 6 (SD 2.2) in the 8-17 years group. JC polyomavirus 
(JCPyV) DNA was detected in 1% of the adenoids, WUPyV in 12% of the tonsils and 28% of the 
adenoids and Merkel cell polyomavirus (MCPyV) was present in 6% and 2% of the tonsils and 
adenoids, respectively. Our study gives new insights on the serological evidence of exposure to PyVs 
during childhood, and on their possible respiratory route of transmission. 
 




Polyomaviruses (PyVs) are non-enveloped viruses with a small, closed, circular, double-strand DNA 
genome. The PyVs genome is divided into three main regions: (i) the early region encoding for the 
large (TAg) and the small t antigens (tAg), (ii) the late region, encoding for the viral capsid proteins 
VP1, VP2 and VP3, and (iii) the non-coding control region (NCCR), containing the bidirectional 
origin of replication.  
The late region of Human PyVs (HPyVs), JC virus (JCPyV), BK virus (BKPyV) and that of the 
monkey PyV Simian virus 40 (SV40) also encodes the agnoprotein (DeCaprio and Garcea, 2013; 
Garren et al, 2015). 
The first Human PyVs (HPyVs) to be isolated from clinical specimens were JCPyV and BKPyV, in 
1971 (Gardner et al. 1971; Padgett et al. 1971). After the primary asymptomatic infection, they remain 
latent in the cells of the urinary tract (Chesters et al. 1983), the central nervous system (CNS) and the 
hematopoietic system (Doerries, 2006), and are causative agents of progressive multifocal 
leukoencephalopathy (PML) and of hemorrhagic cystitis and nephropathy, respectively (Doerries, 
2006; Imperiale, 2000). 
Merkel cell polyomavirus (MCPyV) has subsequently been isolated in Merkel cell carcinoma (MCC), 
a rare and aggressive skin cancer (Feng et al. 2008). The trichodysplasia spinulosa-associated 
polyomavirus (TSPyV), discovered in 2010, can cause a rare skin disease in immunosuppressed 
patients (van der Meijden et al. 2010). 
In the same year as TSPyV, HPyV6 and HPyV7 have been detected in human skin, and HPyV7 has 
been associated with pruritic rush (Schowalter et al. 2010). 
The other newly discovered HPyV, namely KI polyomavirus (KIPyV), WU polyomavirus (WUPyV), 
Lyon IARC polyomavirus (LIPyV), HPyV12, STL polyomavirus (STLPyV), New Jersey 
polyomavirus (NJPyV), HPyV9 and MW polyomavirus (MWPyV), have been isolated from various 
specimens, but they have not been associated with any pathology and their pathogenic role is still 
4 
 
controversial (Allander et al. 2007; Gaynor et al. 2007; Gheit et al. 2017; Korup et al. 2013; Lim et 
al. 2013; Mishra et al. 2014; Scuda et al. 2011; Siebrasse et al. 2012). 
The HPyVs infect in a transversal way the adult population, and their worldwide seroprevalence 
ranges from 20% to 90%, depending on the virus, and on the geographical area (DeCaprio and Garcea, 
2013), implying that healthy individuals are co-infected with several HPyVs. 
Under particular conditions, such as impaired immune functions of the host, HPyV infection can 
reactivate, leading to the development of serious diseases, although the pathogenesis is not fully 
understood (Bhattacharjee and Chattaraj, 2017). 
Currently, few studies have focused on the pediatric population and there is no report regarding the 
seroprevalence of all the newly isolated HPyVs among Italian children. 
In this study we analyze the frequency of serum antibodies against 10 HPyVs, SV40 and the 
Limphotropic PyV (LPyV), as well as the presence of viral DNA in tonsil and adenoid samples, in 
immunocompetent children from Northeast Italy, employing a multiplex technique. 
METHODS 
Subjects and samples 
Between May 2012 and January 2013, 182 samples of peripheral blood, were retrospectively 
analyzed for PyVs seroprevalence, while the presence of the viral genomes was assessed in 82 tonsils 
and 181 adenoids samples.  
Clinical specimens were obtained from a population employed for a previous study (Nicol et al. 2014) 
and consisted of 182 immunocompetent pediatric subjects, who had undergone adeno-tonsillar 
surgery for hypertrophy of adenoids, defined, according to Brodsky’s classification (Brodsky, 1989), 
as adenoids occupying over 80 % of the choanal space, and tonsils graded 3 (30/100) or 4 (70/100), 
at the Otolaryngology Department of the Institute for Maternal and Child Health - IRCCS "Burlo 




Sera were obtained by centrifuging venous blood samples at 1500 rpm for 10 minutes, and were then 
stored at -80 °C until subsequent assessment and analyzed for the presence of antibodies against VP1 
and/or TAg of 12 PyVs: BKPyV (BKVP1, BKTag), JCPyV (JCVP1, JCTAg), LPyV (LPVP1, 
LPTAg), TSPyV (TSVP1, TSTAg), MCPyV (MCPyV344VP1, MCPyV344tAg, MCPyV344TAg,), 
KIPyV (KIVP1), WUPyV (WUVP1), HPyV6 (HPyV6VP1, HPyV6TAg), HPyV7 (HPyV7VP1, 
HPyV7TAg), HPyV9 (HPyV9VP1), HPyV10 (HPyV10VP1, HPyV10TAg) and SV40 (SV40VP1, 
SV40TAg). 
Serological analyses were performed, as previously described, using a multiplex antibody detection 
system based on the fluorescent beads technology, in combination with a glutathione S-transferase 
(GST) capture enzyme-linked immunosorbent assay method (Luminex corporation Austin, Texas) 
(Kjaerheim et al. 2007; Malhotra et al. 2016). Beads were examined on a Luminex 200 analyzer 
(xMAP, Luminex Corp.), that identifies the internal bead color and thus the antigen carried by the 
bead, quantifying the antibodies bound via the median R-phycoerythrin fluorescence intensity (MFI) 
of at least 100 beads of the same bead type. 
Seropositivity for each PyV was defined as virus-specific VP1 antibody >250 MFI and virus-specific 
Tag antibody >400 MFI for Tag, except for seropositivity for MCPyV tag (MFI >200) and SV40 VP1 
(MFI >300)(Waterboer et al. 2006). 
Cut-offs were defined arbitrarily from visual inspection of frequency distribution curves (percentile 
plots) of all sera tested. Stringent criteria were chosen to increase specificity, as suggested by Karagas 
and colleagues, and Michael and colleagues (Karagas et al. 2006; Michael et al. 2008). 
DNA isolation from tonsils/adenoids 
Upon arrival at the laboratory, tonsil and adenoid tissue specimens were processed for DNA 
automated extraction, as previously described (Papa et al. 2016). 
Quantitative Real Time PCR (qPCR) and PCR for the detection of HPyVs genome 
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QPCRs specific for the detection of JCPyV, BKPyV, SV40, MCPyV, WUPyV and KIPyV genomes 
were employed. The choice of these HPyVs was due to the their confirmed or possible adenotropism. 
To measure the viral loads of JCPyV, BKPyV andSV40, the commercial kit Multiplex TaqMan 
qPCR, that simultaneously amplifies the viral genome and the reference human cellular β-globin 
gene, was used, following the manufacturer’s instructions (Euro-RT Polyoma Panel kit; Eurospital 
Spa, Trieste, Italy) (Comar et al. 2014a).  
To assess the presence of MCPyV DNA, samples were analyzed using a quantitative real-time qPCR 
targeting the Tag sequence, as previously described (Maximova et al. 2011). 
WUPyV and KIPyV genomes were searched by conventional PCRs, targeting the WUPyV VP2 and 
KIPyV VP1 sequences, as previously described (Allander et al. 2007; Gaynor et al. 2007). 
As control, the human lymphotropic Epstein-Barr Virus (EBV) was assayed using commercially 
available qPCR kit (Nanogen, Turin, Italy), according to manufacturer’s recommendations(Comar et 
al. 2014b).  
Sequencing of MCPyV PCR amplification products 
Samples resulted positive for MCPyV qPCR, were subjected to conventional PCR using the same 
primers. Amplification products were sequenced to confirm the identity of the virus with an ABI 
PRISM 310 Genetic Analyzer (Applied Biosystem, Foster City, USA), as previously described 
(Cason et al. 2016).Sequence homology search was performed using the Basic Local Alignment 
Search Tool (BLAST) program via the website of the National Center for Biotechnology Information 
(NCBI). 
Statistical analyses 
Statistical analyses were conducted using Stata/IC 14.2 (StataCorp LP, College Station, USA). 
The two-tailed Fisher Exact Test was used to determine whether there were significant differences in 
the distribution of age classes by sex, and to determine the possible association between 
seroprevalence and sex. The same test was used to evaluate the significant association between 
positivity to TAg and VP1, within the same infection. The two-tailed Fisher Exact Test was finally 
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used to evaluate the co-infections among age classes. The Bonferroni correction was applied to the 
level of significance to allow for simultaneous comparisons. A Cuzick’s test for trend was used when 
appropriate. A p value <0.05 was considered as statistically significant, and as the base for the 
Bonferroni correction. 
RESULTS 
Seropositivity to HPyVs 
The main demographic characteristics of the enrolled 182 children are described in Table 1. Results 
of HPyVs seroprevalence by age group are summarized in Table 2 and Fig. 1. Almost 100% of 
subjects were seropositive for at least one HPyV. Seropositivity ranged from 3% for antibodies 
against simian virus 40 (SV40) in children from 0 to 3 years, to 91% for antibodies against WUPyV 
and HPyV10 in children from 8 to 17 years.  
In general, the prevalence of seropositive subjects was higher among children within 8 and 17 years, 
than among those within 0 and 3 years. In particular, among children aged 8-17 years, BKPyV, 
WUPyV and HPyV10 were the most seroprevalent, whereas lymphotropic polyomavirus (LPyV), 
HPyV9 and SV40 were the less seroprevalent. BKPyV (p<0.0001), TSPyV (p<0.01) and HPyV10 
(p<0.05) showed an increasing significant trend of seropositivity among age classes as shown in Fig. 
2, WUPyV showed an increasing trend although not significant.  
The number of different HPyVs against which the subjects were seropositive is shown in Fig. 3, 
panels a-c. The mean number of HPyV for which children were seropositive increased with age: 4 
(SD 1.8) in the 0-3 years group, 5 (SD 1.9) in the 4-7 years group, and 6 (SD 2.2) in the 8-17 years 
group. 
Additionally, the co-presence of antibodies against single HPyV was evaluated and six associations 
were significant (p<0.001): BKPyV-SV40, BKPyV-WUPyV, JCPyV-SV40, LPV-HPyV9, HPyV6-
HPyV7, SV40-HPyV9. 
No significant distribution was observed between sex of subjects and any of the HPyVs. 
HPyVs genomes in tonsil/adenoid tissues  
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JCPyV DNA was detected in 1% of adenoids, WUPyV in 12% of tonsils and in 28% of adenoids. 
MCPyV was present in 6% and 2% of tonsils and adenoids, respectively (Table 3). The lymphotropic 
Epstein-Barr virus (EBV), used as a control, showed the highest percentage of prevalence, 29% in 
tonsils and 42% in adenoids. 
As regard the viral loads, JCPyV in adenoids showed a mean of 1x 103 viral copies/5.5 x 104 cells 
(cells range 4.5 x 103-1.6 x 106); MCPyV showed a mean of 1.0 x 101 viral copies/5.5 x 104 cells in 
adenoids, and of 19.8 viral copies/5.5 x 104 cells in tonsils; EBV in tonsils and adenoids showed a 
range of 4.4 to 33 viral copies/5.5 x 104 cells. 
The sequencing results of the PCR products identified all the amplified strains as belonging to the 
MCPyV genome. Sequences were very similar to the MKL-1 strain isolated from France and Sweden 
confirming the circulation of this strain as previously published by our group (Data not shown) 
(Maximova et al. 2011). 
 
DISCUSSION 
In this retrospective study, for the first time we described the seroprevalence of a panel of 12 PyVs 
in a population of immunocompetent children, living in an area of Northeast Italy. Seroprevalence 
was determined using a multiplex system, by searching antibodies against the structural protein VP1 
and against the viral functional protein Tag, in the serum of the patients. 
Almost all tested subjects were seropositive for at least one virus, confirming that the components of 
the Polyomaviridae family are widespread in the human population and that the primary infection 
occurs early during childhood.  
The most circulating viruses were HPyV10, WUPyV and BKPyV, followed by HPyV6, TSPyV and 
MCPyV. While this is not surprising for WUPyV and BKPyV, whose seropositivity usually ranges 
between 11% and 75% in children less than three years old (Kean et al. 2009; Martel-Jantin et al. 
2014; Miller et al. 2012; Nicol et al. 2013; Sroller et al. 2016; Stolt et al. 2003; Taronna et al. 2013), 
HPyV10 was previously found at lower prevalence in Italy (Nicol et al. 2014).  
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The JCPyV seroprevalence reached 30% in the 8-17 years group, which was similar to the results of 
several previous studies (Chang et al. 2002; Hennes et al. 2016; Kean et al. 2009; Sroller et al. 2014), 
but far from what reported by Elia and colleagues in an Italian recent survey (Elia et al. 2017). These 
differences may be due to the use of an ELISA assay based on multiplex antigens detection, that 
eliminates the issues related to the possible cross-reactivity, or may also be due to the different 
geographical areas (Gossai et al. 2016). 
MCPyV, instead, showed a seroprevalence similar to that previously found in children from different 
areas of Italy (Nicol et al. 2013; Viscidi et al. 2011), and also from the United States (Kean et al., 
2009). 
As expected, since not strictly human, SV40 and LPyV showed the lowest values of seropositivity, 
with peaks of prevalence comprised between 10 and 20% (Kean et al. 2009). HPyV9 also showed 
lower prevalence compared to the other HPyVs and the seroprevalence reported in previous Italian 
and German studies, but it cannot be excluded that its infection might occur later in life (Nicol et al. 
2013; Nicol et al. 2012; Trusch et al. 2012). Recent studies described a cross-reaction between HPyV9 
and LPyV VP1 antibodies, (Trusch et al. 2012; Nicol et al. 2012) indicating that LPyV infection for 
humans needs to be further studied. By only considering the VP1 gene, the seroprevalence results of 
our study show that a cross reaction between HPV9 and LPyV was observed for all positive patients. 
When the Tag antibodies were considered, the serum of only one child showed positivity, confirming 
the existence of a real infection with LPyV, as hypothesized by Delbue and colleagues (2010).  
Interestingly, BKPyV and MCPyV showed the higher seroprevalence in the 0-3 years group, 
compared to the other HPyVs, confirming that MCPyV primary infection could occur earlier during 
childhood than primary infection with the other HPyVs (Martel-Jantin et al. 2013; Signorini et al. 
2014). The trends observed in seroprevalence by age were significant for BKPyV, TSPyV, and 
HPyV10 and may be explained by a continuous viral transmission throughout life (Gossai et al. 2016). 
The mean number of viruses against whom there was seroreactivity increased with age, ranging from 
4 in the 0-3 age group, to 6 in the 8-17 age group, confirming previously published results related to 
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a large general US population (Gossai et al. 2016). Unexpectedly, the MCPyV seroprevalence was 
much higher in the 4-7 years old group of age, than in the 8-17 years old group of age: this result 
could be related to a diminished antibody reactivity against MCPyV over time or, more probably, to 
cohort effects in infection rates.  
Regarding the analysis of co-infections, the significant association between some viruses opens up 
new hypotheses on the role of some PyVs in favoring coinfections by viruses of the same family. 
Our results confirm that the seropositivity against the HPyVs VP1 protein is much more frequent than 
that against the TAg (Malhotra et al., 2016) and that the presence of antibodies against JCPyV and 
BKPyV VP1 remains stable over time, identifying the seroprevalence of VP1 as a reasonable 
indicator of long-term antibody status in epidemiological studies (Antonsson et al. 2010).  
Studying a cohort of young patients undergoing surgery for the ablation of tonsils and/or adenoids, 
we had the opportunity to collect part of the removed tissues and analyze them for the presence of 
some viral sequences. Most of the analyzed viruses resulted negative, whereas JCPyV, WUPyV and 
MCPyV genomes were amplified, with a prevalence comprised between 28% (WUPyV in the 
adenoids) and 1% (JCPyV in the adenoids). These findings confirm that HPyVs can infect the 
lymphoid tissue, especially during the primary infection, which might occur via the respiratory route 
(Kantola et al. 2009; Sadeghi et al. 2014). Thus, we hypothesize that the viruses might initially hit 
tonsils and adenoids, located in the first respiratory tract, and then reach the well-defined latency 
sites, such as kidney or B lymphocytes (Khalili et al., 2003). As expected, viral loads were very low: 
high copy number is usually and significantly associated with disease (Herberhold et al. 2017; 
Sadeghi et al. 2014; Salakova et al. 2016). 
Very recently, Sadeghi and colleagues, using a luminex-based HPyV multiplex assay, with high 
sensitivity and specificity, were able to detect JCPyV, WUPyV, MCPyV, HPyV6, and TSPyV DNA 
altogether in 18% of tonsillar tissues collected from either adults or children. They concluded that 
tonsils might serve as shedding site in HPyV reactivation and thus contribute to HPyV transmission 
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(Sadeghi et al., 2017). Additionally, the detection of other HPyVs, such as KIPyV, BKPyV and also 
SV40 has et al. been reported, confirming these findings (Astegiano et al. 2010; Patel et al., 2008)  
In particular, MCPyV gained more interest as it is the certain etiologic agent of MCC, a rare but 
aggressive tumor affecting predominantly the elderly. Interestingly, this is the first study reporting 
the presence of MCPyV in tonsil and adenoids tissues in pediatric subjects, whereas its presence was 
already demonstrated in the secondary lymphoid tissues of healthy and tumor adult patients (Goh et 
al. 2009; Salakova et al. 2016). As our seroepidemiological data showed, the first contact with 
MCPyV probably occurs in early childhood; subsequently, this virus remains latent without any 
clinical manifestation, but may reactivate in specific conditions, such as immunosuppression, even in 
young subjects (Sourvinos et al. 2015). Shedding of MCPyV from this site of primary diffusion 
during replication might play a role also in MCPyV pathogenesis.  
Although this study gave new insights on the serological evidence of exposure to PyVs during 
childhood, a topic very rarely studied, we are aware of the limitations that affect the survey. 
Firstly, the low homogeneity of the number of samples available among the different age classes 
could have added a bias in the analysis of the results. Furthermore, due to lack of sample, the active 
viral replication was not studied in any other clinical specimen (urine and/or blood) than 
adenoid/tonsil tissues. 
However, seroepidemiological surveys are of great interest in the scientific community working on 
HPyVs, because they are frequently and asymptomatically affecting the healthy human population, 
but they are also associated with important medical conditions, such as nephropathy, demyelinating 
diseases and tumors, and effective therapies are still lacking. 
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Table 1. Main demographic characteristics of the children cohort. 
 
Characteristics Number 
No. Subjects 182 
Ethnicity Caucasian (100%) 
Age in years, median (IQR)* 5.8 (4.4–6.3) 
  Age categories, number (percentage)  
  0-3 years 35 (19 %) 
  4-7 years 125 (69 %) 
  8-17 years 22 (12 %) 
Female in age classes, number (percentage) 86 (47 %) 
  0-3 years 16 (46%) 
  4-7 years 59 (47%) 
  8-17 years 11 (50%) 
















































Table 2. Seropositivity of HPyVs among Italian children aged 0-17 years. 
 
Viruses Antigens 0-3 years 4-7 years 8-17 years 
  n° % n° % n° % 
BKPyV VP1 17 49% 102 82% 19 86% 
VP1 ± TAg 17 49% 102 82% 19 86% 
JCPyV VP1 3 9% 32 26% 5 23% 
VP1 ± TAg 5 14% 42 34% 7 32% 
TSPyV  VP1 7 20% 56 45% 13 59% 
VP1 ± TAg 7 20% 56 45% 13 59% 
MCPyV VP1 12 34% 77 62% 9 41% 
VP1± sTAg ± 
TAg 
12 34% 77 62% 9 41% 
KIPyV  VP1 12 34% 41 33% 10 45% 
WUPyV VP1 25 71% 99 79% 20 91% 
HPyV6 VP1 17 49% 58 46% 14 64% 
VP1 ± TAg 17 49% 60 48% 14 64% 
HPyV7 VP1 7 20% 22 18% 8 36% 
VP1 ± TAg 8 23% 25 20% 8 36% 
HPyV9  VP1 3 9% 10 8% 2 9% 
HPyV10 VP1 25 71% 107 86% 20 91% 
VP1 ± TAg 25 71% 109 87% 20 91% 
SV40 VP1 1 3% 24 19% 1 5% 
VP1 ± TAg 1 3% 25 20% 1 5% 
LPyV VP1 3 9% 7 6% 1 6% 



























Mean viral load 
(virus copies/5.5x104 cells) 
JCPyV 
Tonsils 182 0 / 
Adenoids 181 2 (1%) 1x103 
WUPyV 
Tonsils 50 6 (12%) n.a. 
Adenoids 83 23 (28%) n.a. 
MCPyV 
Tonsils 150 8 (6%) 1x101 






Fig. 1 Seroprevalence of 12 PyVs among the 182 study participants, by age group 
 
Fig. 2 Trend of seropositivity among age classes. Percentage of children positive to antibodies 
against a) BKPyV (VP1 ± TAg); b) TSPyV (VP1 ± TAg); c) HPyV10 (VP1 ± TAg), and d) 
WUPyV (VP1) 
 
Fig. 3 Number of different PyVs against which a subject tested positive, by age: panel a) 0-3 years; 
panel b) 4-7 years; panel c) 8-17 years.  
 
